<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">24642619</PMID>
        <DateCompleted>
            <Year>2014</Year>
            <Month>06</Month>
            <Day>05</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2018</Year>
            <Month>11</Month>
            <Day>13</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1532-1827</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>110</Volume>
                    <Issue>8</Issue>
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Apr</Month>
                        <Day>15</Day>
                    </PubDate>
                </JournalIssue>
                <Title>British journal of cancer</Title>
                <ISOAbbreviation>Br. J. Cancer</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Manipulating the expression of chemokine receptors enhances delivery and activity of cytokine-induced killer cells.</ArticleTitle>
            <Pagination>
                <MedlinePgn>1992-9</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1038/bjc.2014.140</ELocationID>
            <Abstract>
                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Cytokine-induced killer (CIK) cells are ex vivo-expanded immune cells that express NK-cell and T-cell markers and that are routinely used in the treatment of many cancers. One key advantage of CIK cells is their ability to efficiently traffic to many solid tumours. Although likely to be mediated by chemokine receptor (CKR) expression, a thorough examination of the mechanism of tumour targeting has not been previously explored.</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">Here, human CIK cell expansions were examined for the level, profile and kinetics of CKR expression.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">It was found that CIK cells express a panel of CKRs, with considerable variation between donors. Importantly, CKR levels dropped considerably beyond 14 days in culture, being significantly reduced by day 28 (the time at which cytolytic activity peaked). As such, CIK preparations that are used clinically may not have optimal CKR expression. Several approaches were found to re-stimulate CKR cell-surface levels at these later time points. These approaches also enhanced cytolytic activity in vitro and were demonstrated to increase both in vivo tumour trafficking and anti-tumour activity in mouse models.</AbstractText>
                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Simple modifications of the CIK expansion protocol could therefore be used to significantly enhance the anti-tumour effects of this therapy.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Zou</LastName>
                    <ForeName>Y</ForeName>
                    <Initials>Y</Initials>
                    <AffiliationInfo>
                        <Affiliation>1] Department of Surgey, University of Pittsburgh Cancer Institute, University of Pittsburgh, Pittsburgh, PA, USA [2] Institute of Clinical and Basic Medical Sciences, The First People's Hospital of Yunnan Province (The Kunhua Affiliated Hospital of Kunming University of Science and Technology), Kunming, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Li</LastName>
                    <ForeName>F</ForeName>
                    <Initials>F</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Oncology, First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hou</LastName>
                    <ForeName>W</ForeName>
                    <Initials>W</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Surgey, University of Pittsburgh Cancer Institute, University of Pittsburgh, Pittsburgh, PA, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Sampath</LastName>
                    <ForeName>P</ForeName>
                    <Initials>P</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Surgey, University of Pittsburgh Cancer Institute, University of Pittsburgh, Pittsburgh, PA, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zhang</LastName>
                    <ForeName>Y</ForeName>
                    <Initials>Y</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Oncology, First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Thorne</LastName>
                    <ForeName>S H</ForeName>
                    <Initials>SH</Initials>
                    <AffiliationInfo>
                        <Affiliation>1] Department of Surgey, University of Pittsburgh Cancer Institute, University of Pittsburgh, Pittsburgh, PA, USA [2] Department of Immunology, University of Pittsburgh Cancer Institute, University of Pittsburgh, Pittsburgh, PA, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <GrantList CompleteYN="Y">
                <Grant>
                    <GrantID>P30 CA047904</GrantID>
                    <Acronym>CA</Acronym>
                    <Agency>NCI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>R01 CA140215</GrantID>
                    <Acronym>CA</Acronym>
                    <Agency>NCI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>P30 CA047904-21S3</GrantID>
                    <Acronym>CA</Acronym>
                    <Agency>NCI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
            </GrantList>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>03</Month>
                <Day>18</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>England</Country>
            <MedlineTA>Br J Cancer</MedlineTA>
            <NlmUniqueID>0370635</NlmUniqueID>
            <ISSNLinking>0007-0920</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D019707">Receptors, Chemokine</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D049109" MajorTopicYN="N">Cell Proliferation</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D055612" MajorTopicYN="N">Cytokine-Induced Killer Cells</DescriptorName>
                <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
                <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D003602" MajorTopicYN="Y">Cytotoxicity, Immunologic</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005434" MajorTopicYN="N">Flow Cytometry</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006367" MajorTopicYN="N">HeLa Cells</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D007694" MajorTopicYN="N">Killer Cells, Natural</DescriptorName>
                <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
                <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D009369" MajorTopicYN="N">Neoplasms</DescriptorName>
                <QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
                <QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D019707" MajorTopicYN="N">Receptors, Chemokine</DescriptorName>
                <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
                <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2013</Year>
                <Month>11</Month>
                <Day>15</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2014</Year>
                <Month>02</Month>
                <Day>19</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>02</Month>
                <Day>24</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>3</Month>
                <Day>20</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>3</Month>
                <Day>20</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>6</Month>
                <Day>6</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">24642619</ArticleId>
            <ArticleId IdType="pii">bjc2014140</ArticleId>
            <ArticleId IdType="doi">10.1038/bjc.2014.140</ArticleId>
            <ArticleId IdType="pmc">PMC3992500</ArticleId>
        </ArticleIdList>
        <ReferenceList>
            <Reference>
                <Citation>Blood. 2001 May 15;97(10):2923-31</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">11342413</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer Res. 2002 Oct 15;62(20):5785-91</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">12384539</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Natl Cancer Inst. 1991 Mar 20;83(6):433-7</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">1999850</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Gynecol Oncol. 1993 Feb;48(2):203-9</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">8428692</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Exp Hematol. 1993 Dec;21(13):1673-9</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">7694868</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Immunol. 1994 Aug 15;153(4):1687-96</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">7519209</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer Biother Radiopharm. 2013 May;28(4):303-9</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23506427</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Science. 2006 Mar 24;311(5768):1780-4</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">16556847</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Exp Hematol. 2006 Sep;34(9):1219-29</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">16939815</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Blood. 2008 Sep 15;112(6):2563-74</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">18565854</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Lancet Oncol. 2013 May;14(6):e218-28</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23639322</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Exp Hematol. 2013 Jun;41(6):508-17</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23403007</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Surgery. 2013 Sep;154(3):486-95</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23890748</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Biol Blood Marrow Transplant. 2005 Mar;11(3):181-7</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">15744236</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
    </PubmedData>
</PubmedArticle>

</PubmedArticleSet>